Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference
Tevogen Bio (Nasdaq: TVGN) shared insights from a fireside chat with Microsoft during the J.P. Morgan Healthcare Conference, focusing on AI-driven drug development. The discussion featured Microsoft's Global Chief Medical Officer Dr. David Rhew and Tevogen's CIO Mittul Mehta, head of Tevogen.AI.
The speakers highlighted how AI and machine learning are revolutionizing drug discovery, with AI-powered tools reducing computational tasks from thousands of years to months. They emphasized the importance of multimodal data AI, which processes diverse data sources including imaging, genomics, and health records.
Tevogen Bio is developing curated datasets for reliable AI models, while emphasizing data governance and privacy-preserving techniques. The company's AI initiatives align with its commitment to patient equity, aiming to achieve cost and time efficiencies that could result in patient savings.
Tevogen Bio (Nasdaq: TVGN) ha condiviso informazioni da una chiacchierata informale con Microsoft durante la Conferenza Sanitaria J.P. Morgan, concentrandosi sullo sviluppo di farmaci guidato dall'IA. La discussione ha avuto come protagonisti il Chief Medical Officer Globale di Microsoft, Dr. David Rhew, e il CIO di Tevogen, Mittul Mehta, capo di Tevogen.AI.
I relatori hanno sottolineato come l'IA e l'apprendimento automatico stiano rivoluzionando la scoperta di farmaci, con strumenti potenziati dall'IA che riducono i compiti computazionali da migliaia di anni a pochi mesi. Hanno enfatizzato l'importanza dell'IA multimodale, che elabora fonti di dati diverse, comprese immagini, genomica e cartelle cliniche.
Tevogen Bio sta sviluppando set di dati curati per modelli di IA affidabili, ponendo l'accento sulla governance dei dati e su tecniche che preservano la privacy. Le iniziative di IA dell'azienda sono in linea con il suo impegno per l'equità dei pazienti, mirando a raggiungere efficienze in termini di costi e tempi che potrebbero comportare risparmi per i pazienti.
Tevogen Bio (Nasdaq: TVGN) compartió información de una charla informal con Microsoft durante la Conferencia de Salud J.P. Morgan, centrándose en el desarrollo de medicamentos impulsado por IA. La discusión contó con la participación del Director Médico Global de Microsoft, Dr. David Rhew, y el CIO de Tevogen, Mittul Mehta, jefe de Tevogen.AI.
Los oradores destacaron cómo la IA y el aprendizaje automático están revolucionando el descubrimiento de fármacos, con herramientas impulsadas por IA que reducen las tareas computacionales de miles de años a meses. Enfatizaron la importancia de la IA de datos multimodales, que procesa diversas fuentes de datos, incluidas imágenes, genómica y registros de salud.
Tevogen Bio está desarrollando conjuntos de datos curados para modelos de IA confiables, mientras enfatiza la gobernanza de datos y técnicas que preservan la privacidad. Las iniciativas de IA de la empresa están alineadas con su compromiso con la equidad del paciente, con el objetivo de lograr eficiencias en costos y tiempo que podrían dar como resultado ahorros para los pacientes.
Tevogen Bio (Nasdaq: TVGN)는 J.P. Morgan 헬스케어 컨퍼런스에서 Microsoft와 진행된 담화에서 AI 기반 약물 개발에 대한 통찰을 공유했습니다. 이 논의에는 Microsoft의 글로벌 최고 의료 책임자 Dr. David Rhew와 Tevogen.AI의 책임자인 Tevogen의 CIO Mittul Mehta가 참여했습니다.
발표자들은 AI와 머신러닝이 약물 발견을 어떻게 혁신하고 있는지를 강조했으며, AI 기반 도구가 수천 년의 계산 작업을 몇 개월로 단축한다고 밝혔습니다. 그들은 이미징, 유전체학 및 건강 기록을 포함한 다양한 데이터 소스를 처리하는 다중 모드 데이터 AI의 중요성을 강조했습니다.
Tevogen Bio는 신뢰할 수 있는 AI 모델을 위한 큐레이션된 데이터 세트를 개발하고 있으며, 데이터 관리 및 프라이버시 보호 기술에 중점을 두고 있습니다. 회사의 AI 이니셔티브는 환자 형평성에 대한 약속과 일치하고 있으며, 환자에게 절약이 가능한 비용 및 시간 효율성을 달성하는 것을 목표로 하고 있습니다.
Tevogen Bio (Nasdaq: TVGN) a partagé des informations lors d'une discussion informelle avec Microsoft pendant la Conférence de Santé J.P. Morgan, en se concentrant sur le développement de médicaments piloté par l'IA. La discussion a été animée par le directeur médical mondial de Microsoft, Dr. David Rhew, et le CIO de Tevogen, Mittul Mehta, responsable de Tevogen.AI.
Les intervenants ont souligné comment l'IA et l'apprentissage automatique révolutionnent la découverte de médicaments, avec des outils propulsés par l'IA réduisant les tâches de calcul de milliers d'années à quelques mois. Ils ont mis en avant l'importance des données multimodales en IA, qui traitent diverses sources de données, y compris l'imagerie, la génomique et les dossiers de santé.
Tevogen Bio développe des ensembles de données soigneusement sélectionnés pour des modèles d'IA fiables, tout en mettant l'accent sur la gouvernance des données et les techniques préservant la vie privée. Les initiatives d'IA de l'entreprise sont en accord avec son engagement envers l'équité des patients, visant à atteindre des gains de coûts et de temps qui pourraient entraîner des économies pour les patients.
Tevogen Bio (Nasdaq: TVGN) teilte Einblicke aus einem informellen Gespräch mit Microsoft während der J.P. Morgan Healthcare Conference, mit einem Fokus auf KI-gesteuerte Arzneimittelentwicklung. An der Diskussion nahmen der Globale Chief Medical Officer von Microsoft, Dr. David Rhew, und der CIO von Tevogen, Mittul Mehta, Leiter von Tevogen.AI, teil.
Die Referenten hoben hervor, wie KI und maschinelles Lernen die Arzneimittelforschung revolutionieren, indem KI-gestützte Werkzeuge die Rechenaufgaben von Tausenden von Jahren auf Monate verkürzen. Sie betonten die Bedeutung von multimodalen Daten-KI, die verschiedene Datenquellen wie Bilder, Genomik und Gesundheitsakten verarbeitet.
Tevogen Bio entwickelt kuratierte Datensätze für zuverlässige KI-Modelle und betont gleichzeitig Datenverwaltung und datenschutzfreundliche Techniken. Die KI-Initiativen des Unternehmens stehen im Einklang mit dem Engagement für Chancengleichheit bei Patienten und zielen darauf ab, Kosten- und Zeiteffizienzen zu erreichen, die zu Einsparungen für Patienten führen könnten.
- Implementation of AI/ML technology showing significant reduction in drug development timelines
- Development of proprietary AI platform (Tevogen.AI) for drug discovery
- Strategic partnership with Microsoft for AI implementation
- None.
Insights
This fireside chat reveals Tevogen Bio's ambitious AI strategy, positioning itself at the intersection of biotechnology and artificial intelligence. The partnership with Microsoft's healthcare division, represented by their Global CMO, signals a sophisticated approach to AI implementation that goes beyond surface-level applications.
Several key developments warrant investor attention:
- The company's Tevogen.AI platform is already delivering measurable efficiency gains in both cost and time - critical factors in drug development where traditional R&D costs can exceed
$1 billion per successful drug - Their focus on multimodal data analysis, combining imaging, genomics and health records, represents a more advanced AI implementation than many competitors who focus solely on single-modal applications
- The emphasis on curated datasets and wet-lab validation demonstrates a pragmatic approach that could reduce the risk of AI-related failures
However, investors should consider several critical factors:
- While the AI strategy is promising, the company remains in clinical-stage with no marketed products yet
- The focus on cost efficiency and patient equity, while admirable, may impact profit margins in future commercialization
- The competitive advantage period may be as other biotechs rapidly adopt similar AI capabilities
The collaboration with Microsoft adds credibility to Tevogen's AI initiatives, but the real test will be translating these technological capabilities into successful drug development outcomes.
WARREN, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Company” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T-cell therapeutics for infectious diseases and cancers, today announced key insights from its recent fireside chat during the J.P. Morgan Healthcare Conference. Utilizing artificial intelligence (AI) and machine learning (ML) has been critical for Tevogen Bio, given its core commitment to patient equity. By applying ML through Tevogen.AI, the company has already achieved notable cost and time efficiencies, developments that could translate directly into savings for patients. The discussion featured Dr. David Rhew, Global Chief Medical Officer & VP of Healthcare at Microsoft (Nasdaq: MSFT), and Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, who shared their vision for how AI is revolutionizing drug development and healthcare delivery.
Accelerating Drug Discovery
In the fireside chat, Dr. Rhew described how AI-driven modeling and simulation are drastically reducing the time required to identify and develop drug candidates. He provided an example where a computational task that previously may have taken “thousands of years” using traditional approaches was completed in a matter of months thanks to AI-powered tools. These breakthroughs, Dr. Rhew noted, illustrate a paradigm shift in what is now possible in the pharmaceutical research and development process.
The Rise of Generative AI and Multimodal Data
Both speakers emphasized that while generative AI has garnered widespread attention, next-generation approaches extend beyond simply creating text or images. According to Dr. Rhew, organizations are increasingly deploying multimodal data AI, which processes data from diverse sources, such as imaging, genomics, and electronic health records, to reveal novel insights. Generative AI then serves as a powerful query engine on top of these “foundation models,” enabling seamless interpretation and conversion of complex data into clinically relevant results and formats.
Ensuring Data Quality, Privacy, and Responsible AI
Speaking to Tevogen Bio’s AI developments, Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, highlighted, “We are creating curated datasets, supported by wet-lab research, to fuel the creation of reliable foundational AI models." Dr. Rhew echoed the need for “clean” and “annotated” datasets, stating, “AI is like a powerful engine. It can take us anywhere, but it needs clean, curated data as fuel. Crude data won't work; it must be refined and properly annotated to be useful." Both speakers also stressed the importance of strong data governance and privacy-preserving techniques, such as federated learning and confidential compute, which enable secure collaboration on sensitive datasets without exposing proprietary information or intellectual property. Dr. Rhew underscored that responsible AI requires bias mitigation, transparency, and continuous oversight. Mr. Mehta commended Microsoft’s commitment to these principles, stating that responsible development practices are vital to ensuring equitable and safe adoption of AI technologies in healthcare.
“AI is the next industrial revolution and could be humanity’s greatest leap yet. I commend efforts similar to Stargate for their investment in forward-thinking and transformative technologies,” said Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio. “Drug development will undoubtedly improve with the power of AI, but the key is to seamlessly bridge medical science and technology. As a biotech focused on pioneering through AI, we remain committed to advancing affordable medical innovation.”
About Tevogen Bio
Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Bio Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8f6d82a7-ae1f-40ac-888f-dbd580e3af4b
FAQ
How is Tevogen Bio (TVGN) using AI to reduce drug development costs?
What is the partnership between Tevogen Bio (TVGN) and Microsoft in AI development?
What efficiency improvements has Tevogen Bio (TVGN) achieved with AI in drug development?
How does Tevogen.AI handle data privacy and security in drug development?
